|
5th International AIDS Society Conference on HIV Pathogenesis and TreatmentCape Town - July 19 - 22, 2009 |
THE IMPACT OF HOME-BASED COMPARED WITH FACILITY-BASED HIV-CARE ON VIROLOGIC FAILURE AND MORTALITY: A CLUSTER RANDOMISED TRIAL
IAS Conf HIV Pathog Treat 2009 Jul 19-22;5th: Abstract No. MOAD101
S. Jaffar
1, B. Amuron2, J. Levin2, J. Birungi3, G. Namara2, C. Nabiryo3, A. Coutinho4, H. Grosskurth2,5
1London School Hygiene and Tropical Medicine, Epidemiology and Population Health, London, United Kingdom, 2MRC/UVRI Uganda Research Unit on AIDS, Entebbe, Uganda, 3The AIDS Support Organisation (TASO), Kampala, Uganda, 4Infectious Diseases Institute, Makerere University, Kampala, Uganda, 5London School Hygiene and Tropical Medicine, London, United Kingdom
BACKGROUND: Because of health system constraints, identifying ways to increase access to antiretroviral therapy (ART) in Africa is an urgent priority. We conducted a cluster-randomised trial to compare home-based care (HBC) with facilitybased (FBC).
METHODS: Trial was conducted at The AIDS Support Organisation (TASO) clinic in Jinja, Uganda under normal health service conditions. ART was initiated at the clinic. 44 clusters were randomised to HBC or FBC. In HBC, support, monitoring and drug delivery was done monthly in the home by lay workers and patients attended clinic 6-monthly for routine evaluation. In FBC, patients attended clinic monthly to collect drugs and were evaluated routinely 3-monthly. Evaluations were done mostly by junior clinicians and experienced counsellors. Standard regimens were used. Analyses adjusted for CD4 count and clustering. Virologic failure was defined as RNA>500 copies /ml.
RESULTS: 859 patients (22 clusters) were randomised to HBC and 594 (22 clusters) to FBC. Enrolment started February 2005 and follow-up ended January 2009. 24(2%) refused to enrol (21 HBC, 3 FBC), 119 (8%) withdrew (60 HBC, 59 FBC) and 34 (2%) were lost-to-follow-up (20 HBC, 14 FBC). Baseline CD4 count was < 100 cells /µl in 431 (50%) HBC and 245 (41%) in FBC. Mean number of clinic visits per patient was 8 in HBC and 26 in FBC. Mortality (95% CI) /100 person years was 6.28 (5.24, 7.53) in HBC and 6.48 (5.20, 8.07) in FBC: adjusted rate ratio (aRR) 0.96 (0.71, 1.28). 117 (13.6%) in HBC compared with 80 (13.5%) in FBC had virologic failure (aRR 0.96, 95% CI 0.71, 1.28). At final visit, 943 (65%) were followed-up with undetectable plasma RNA (HBC 66%, FBC 64%).
CONCLUSIONS: Excellent outcomes were achieved in both facility and home-based HIV care. Complex treatments in Africa can be delivered effectively nearer to patients' homes without frequent support from clinical staff.
Download PDF of this abstract.
Download Power Point Presentation.
2009-07-22
MOAD101
Oral Abstract Session MOAD1 - Innovative Methods for Effectively Delivering HIV Care Interventions
Copyright © 2009 - International AIDS Society (IAS). All information and content relating to the abstracts from the 5th International AIDS Society Conference on HIV Pathogenesis and Treatment, such as text, graphics, logos, button icons, images, audio clips, and software is protected by copyright. Permission is hereby granted for the non-commercial use or reproduction of the information on this web site, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the Elton John AIDS Foundation, National Library of Medicine, AIDS Walk of Orange County, and donations from users like you. Always watch for outdated information. This article first appeared in 2009. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2009. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. Permission is hereby granted for the non-commercial use or reproduction of the information herein, provided that the use of such information is accompanied by an acknowledgement that IAS is the source of the information and the name of the author of the article.